Stage I
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors (NCT06772610) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-03-15 |
| Anti PD-1 Neo-adjuvant Treatment for NSCLC (NCT02938624) | Jair Bar, M.D., Ph.D. | 2017-01-07 |
Track Stage I automatically
Every clearance here is in the API, with alerts when new ones post.